<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00822341</url>
  </required_header>
  <id_info>
    <org_study_id>TG-0054-01</org_study_id>
    <nct_id>NCT00822341</nct_id>
  </id_info>
  <brief_title>Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of TG-0054 With Single IV Doses Escalation in Healthy Volunteers</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Sequential Ascending Single Intravenous Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TG-0054 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GPCR Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GPCR Therapeutics, Inc.</source>
  <brief_summary>
    <textblock>
      TG-0054 is a CXCR4 antagonist with stem cell mobilization effect as proven in animal model,&#xD;
      this is the fist in human study to investigator the safety, tolerability and PK/PD in healthy&#xD;
      subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the safety and tolerability for a single IV dose of TG-0054</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>To determine the maximum tolerated dose (MTD) of TG-0054</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the plasma pharmacokinetics (PK) profile of TG-0054</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the pharmacodynamic (PD) effects of TG-0054 via CD34+stem cell, CD133+ progenitor cell counts; white blood cell (WBC), red blood cell (RBC), platelet, and differential counts</measure>
  </secondary_outcome>
  <enrollment type="Actual">64</enrollment>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TG-0054</intervention_name>
    <description>0.10, 0.14, 0.28, 0.56, 1.12, 2.24, 3.14, and 4.40 mg/kg of TG-0054/placebo via 15 min IV infusion</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male or female 18 to 45 years of age inclusive&#xD;
&#xD;
          -  Body mass index (BMI) in the range of 19.0 to 30.0 kg/m² and body weight ≥ 50 kg&#xD;
             inclusive&#xD;
&#xD;
          -  Good physical and mental health status determined on the basis of the medical history&#xD;
             and a general clinical examination&#xD;
&#xD;
          -  Subjects must have used a consistent form of acceptable oral birth control or the&#xD;
             double barrier method (intrauterine device (IUD) plus condom, spermicidal gel plus&#xD;
             condom) for at least 3 months prior to study initiation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any medical condition (other than a self-limited illness) that requires ongoing and&#xD;
             current medical attention&#xD;
&#xD;
          -  History of any other hematologic disorders including thromboembolic disease or anemia&#xD;
&#xD;
          -  Severe trauma, fracture, major surgery, or biopsy of a parenchymal organ within the&#xD;
             past 3 months&#xD;
&#xD;
          -  Any medical, psychiatric, social condition, occupational reason or other&#xD;
             responsibility that, in the judgment of the investigator, is a contraindication to&#xD;
             protocol participation or impairs a volunteer's ability to give informed consent&#xD;
&#xD;
          -  Subjects who currently smoke (intake nicotine or nicotine-containing products) or have&#xD;
             given up smoking for less than 6 months before the first administration of study drug&#xD;
&#xD;
          -  Subjects who are carriers of the Hepatitis B surface antigen (HBsAg) or Hepatitis C&#xD;
             antibody or who are Human Immunodeficiency Virus (HIV) antibody positive&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald Goldwater, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>PAREXEL Clinical Pharmacology Research Unit Harbor Hospital Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PAREXEL Clinical Pharmacology Research Unit Harbor Hospital Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 13, 2009</study_first_submitted>
  <study_first_submitted_qc>January 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2009</study_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

